New pill takes on stubborn lung cancer in major trial
NCT ID NCT06281964
First seen Dec 29, 2025 · Last updated May 24, 2026 · Updated 22 times
Summary
This phase 3 study tests a new oral drug, PLB1004, against standard chemotherapy for people with advanced non-small-cell lung cancer that has a specific EGFR mutation (exon 20 insertion). About 327 adults with this rare, hard-to-treat cancer will be enrolled. The main goal is to see if PLB1004 delays cancer growth better than chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangzhou, 510080, China
Conditions
Explore the condition pages connected to this study.